Holen Sie sich die Stockscreener-App
15.65
9.29%
1.33
Handel nachbörslich:
15.34
-0.31
-1.98%
Schlusskurs vom Vortag:
$14.32
Offen:
$15.06
24-Stunden-Volumen:
317.48K
Relative Volume:
1.29
Marktkapitalisierung:
$2.02B
Einnahmen:
$65.48M
Nettoeinkommen (Verlust:
$-94.46M
KGV:
-21.22
EPS:
-0.7375
Netto-Cashflow:
$-71.18M
1W Leistung:
+6.97%
1M Leistung:
-7.45%
6M Leistung:
-4.05%
1J Leistung:
+10.91%
1-Tages-Spanne:
$15.06
$15.89
1-Wochen-Bereich:
$14.02
$15.89
52-Wochen-Spanne:
$9.61
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Firmenname
Mesoblast Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare MESO vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.65 | 1.85B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-12-23 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-24 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-29 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-23 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | Eingeleitet | William Blair | Outperform |
| 2022-12-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-06 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-12-22 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-12-04 | Herabstufung | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2020-05-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-31 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-03-22 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2017-06-08 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Mesoblast Ltd Adr Aktie (MESO) Neueste Nachrichten
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - inkl
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors - Nasdaq
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall (NASDAQ:MESO) - Seeking Alpha
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
MESOMesoblast Ltd ADR Short Interest - Finviz
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
MESO Financial Statements & ChartsMesoblast LtdAdr MacroTrends - CMLviz
MESO Pivot Points, Technical Analysis and Moving AveragesMesoblast LtdAdr Technicals - CMLviz
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod - Yahoo Finance
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
How many stocks fighting COVID-19 have maintained their momentum? - Stockhead
Mesoblast Stock Soars on Promise of Cellular Medicine - Nanalyze
MESO Stock Price and Chart — NASDAQ:MESO - TradingView
Finanzdaten der Mesoblast Ltd Adr-Aktie (MESO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):